Rapamycin extends maximal lifespan in cancer-prone mice - PubMed (original) (raw)
Rapamycin extends maximal lifespan in cancer-prone mice
Vladimir N Anisimov et al. Am J Pathol. 2010 May.
Abstract
Aging is associated with obesity and cancer. Calorie restriction both slows down aging and delays cancer. Evidence has emerged that the nutrient-sensing mammalian target of rapamycin (mTOR) pathway is involved in cellular and organismal aging. Here we show that the mTOR inhibitor rapamycin prevents age-related weight gain, decreases rate of aging, increases lifespan, and suppresses carcinogenesis in transgenic HER-2/neu cancer-prone mice. Rapamycin dramatically delayed tumor onset as well as decreased the number of tumors per animal and tumor size. We suggest that, by slowing down organismal aging, rapamycin delays cancer.
Figures
Figure 1
Effects of rapamycin on age-related weight gain and lifespan of female transgenic HER-2/neu mice. A: Effect of rapamycin on body weight in female transgenic HER-2/neu mice. The rapamycin group of animals received 1.5 mg/kg rapamycin three times a week for a period of 2 weeks followed by 2-week intervals without rapamycin. Mice in control group received solvent without rapamycin. Mice were weighed once a month. B: Effect of rapamycin on mice survival. Mice were observed throughout their lifespan, and all animals were autopsied. Distributions of lifespan in control and experimental groups were significantly different (log-rank test, P = 0.00588). Survival dynamics showed significant differences.
Figure 2
Suppression of carcinogenesis by rapamycin. A: Effect of rapamycin on tumor yield curves in female transgenic HER-2/neu mice. B: Effect of rapamycin on cumulative number of tumors in female transgenic HER-2/neu mice. C: Effect of rapamycin on distribution of mice with multiple mammary tumors in female transgenic HER-2/neu mice. Asterisks mean that according to the Fisher exact test for count data the distributions of the number of mice bearing 1 to 4, 5 to 7, and 8 to 10 tumors is significant with P = 0.0006959.
Similar articles
- Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin.
Popovich IG, Anisimov VN, Zabezhinski MA, Semenchenko AV, Tyndyk ML, Yurova MN, Blagosklonny MV. Popovich IG, et al. Cancer Biol Ther. 2014 May;15(5):586-92. doi: 10.4161/cbt.28164. Epub 2014 Feb 20. Cancer Biol Ther. 2014. PMID: 24556924 Free PMC article. - Longevity, aging and rapamycin.
Ehninger D, Neff F, Xie K. Ehninger D, et al. Cell Mol Life Sci. 2014 Nov;71(22):4325-46. doi: 10.1007/s00018-014-1677-1. Cell Mol Life Sci. 2014. PMID: 25015322 Free PMC article. Review. - Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice.
Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Rosenfeld SV, Blagosklonny MV. Anisimov VN, et al. Cell Cycle. 2011 Dec 15;10(24):4230-6. doi: 10.4161/cc.10.24.18486. Epub 2011 Dec 15. Cell Cycle. 2011. PMID: 22107964 - The use of calorie restriction mimetics to study aging.
Kitada M, Koya D. Kitada M, et al. Methods Mol Biol. 2013;1048:95-107. doi: 10.1007/978-1-62703-556-9_8. Methods Mol Biol. 2013. PMID: 23929100 - Once again on rapamycin-induced insulin resistance and longevity: despite of or owing to.
Blagosklonny MV. Blagosklonny MV. Aging (Albany NY). 2012 May;4(5):350-8. doi: 10.18632/aging.100461. Aging (Albany NY). 2012. PMID: 22683661 Free PMC article. Review.
Cited by
- Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging.
Leontieva OV, Paszkiewicz GM, Blagosklonny MV. Leontieva OV, et al. Aging (Albany NY). 2012 Dec;4(12):899-916. doi: 10.18632/aging.100528. Aging (Albany NY). 2012. PMID: 23443503 Free PMC article. - Inflammaging: disturbed interplay between autophagy and inflammasomes.
Salminen A, Kaarniranta K, Kauppinen A. Salminen A, et al. Aging (Albany NY). 2012 Mar;4(3):166-75. doi: 10.18632/aging.100444. Aging (Albany NY). 2012. PMID: 22411934 Free PMC article. - Obesity, energy balance, and cancer: new opportunities for prevention.
Hursting SD, Digiovanni J, Dannenberg AJ, Azrad M, Leroith D, Demark-Wahnefried W, Kakarala M, Brodie A, Berger NA. Hursting SD, et al. Cancer Prev Res (Phila). 2012 Nov;5(11):1260-72. doi: 10.1158/1940-6207.CAPR-12-0140. Epub 2012 Oct 3. Cancer Prev Res (Phila). 2012. PMID: 23034147 Free PMC article. Review. - Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug.
Mercier I, Camacho J, Titchen K, Gonzales DM, Quann K, Bryant KG, Molchansky A, Milliman JN, Whitaker-Menezes D, Sotgia F, Jasmin JF, Schwarting R, Pestell RG, Blagosklonny MV, Lisanti MP. Mercier I, et al. Am J Pathol. 2012 Jul;181(1):278-93. doi: 10.1016/j.ajpath.2012.03.017. Epub 2012 Jun 13. Am J Pathol. 2012. PMID: 22698676 Free PMC article. - Pharmacological Approaches to Decelerate Aging: A Promising Path.
Hassani B, Goshtasbi G, Nooraddini S, Firouzabadi N. Hassani B, et al. Oxid Med Cell Longev. 2022 Jul 11;2022:4201533. doi: 10.1155/2022/4201533. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 35860429 Free PMC article. Review.
References
- Guarente L, Kenyon C. Genetic pathways that regulate ageing in model organisms. Nature. 2000;408:255–262. - PubMed
- Demidenko ZN, Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle. 2008;7:3355–3361. - PubMed
- Vellai T, Takacs-Vellai K, Zhang Y, Kovacs AL, Orosz L, Muller F. Genetics: influence of TOR kinase on lifespan in C. elegans. Nature. 2003;426:620. - PubMed
- Jia K, Chen D, Riddle DL. The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. Development. 2004;131:3897–3906. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous